Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

180
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
180
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

924
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
924
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.0K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complex signal identification as a marker of left atrial remodeling and very early recurrence after atrial fibrillation ablation.

Heart rhythm O2·2026
Same author

The prognostic significance of pharmacological therapy after cardiac resynchronization therapy.

Fukushima journal of medical science·2026
Same author

Impact of Right Superior Pulmonary Vein Anatomy and 31-mm Cryoballoon Use on the Risk of Phrenic Nerve Injury During Cryoablation for Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same author

Simultaneous measurements of HERFD-XANES, RXES and RIXS of caesium using a transition-edge sensor.

Journal of synchrotron radiation·2026
Same author

Higher very short-term blood pressure variability is associated with lower atrial fibrillation recurrence after catheter ablation.

Frontiers in cardiovascular medicine·2026
Same author

Prolonged low-dose tPA ameliorates coagulopathy and organ injury in an LPS-induced rat DIC model.

International journal of hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in pathogenesis, diagnosis, and therapeutic strategies for POEMS syndrome].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Recent advances in management of systemic AL amyloidosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same journal

[Treatment strategies for relapsed or refractory multiple myeloma: proposals for optimal treatment sequencing].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
See all related articles

Related Experiment Video

Updated: Dec 12, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K

[Acquired factor V inhibitor].

Shinya Yamada1,2, Hidesaku Asakura2

  • 1Department of Hematology, Toyama Prefectural Central Hospital.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|August 8, 2020
PubMed
Summary
This summary is machine-generated.

Acquired factor V inhibitor (FV-INH) is a rare condition causing bleeding or thrombosis. Spontaneous resolution occurs in 50% of cases, with treatment reserved for symptomatic patients.

Keywords:
Acquired factor V inhibitorHepaplastintest (HPT)Thrombotest (TT)

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.1K

Related Experiment Videos

Last Updated: Dec 12, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.1K

Area of Science:

  • Hematology
  • Immunology

Background:

  • Acquired factor V inhibitor (FV-INH) is a rare autoimmune disorder with an incidence of 0.023-0.09 per million person-years.
  • FV-INH can be triggered by infections, drugs, surgery, malignancy, or autoimmune diseases.
  • Clinical presentation ranges from asymptomatic to life-threatening bleeding or thrombosis.

Purpose of the Study:

  • To review the epidemiology, pathophysiology, diagnosis, and management of acquired factor V inhibitor.

Main Methods:

  • Literature review of acquired factor V inhibitor cases since 1955.
  • Analysis of diagnostic criteria including prolonged PT and APTT, inhibitor patterns, and decreased factor V activity.
  • Review of treatment strategies including hemostatic and immunosuppressive therapies.

Main Results:

  • Approximately 200 cases of FV-INH have been reported globally.
  • Diagnosis relies on laboratory findings: prolonged PT/APTT, inhibitor pattern, and low factor V activity.
  • Spontaneous resolution occurs in about 50% of cases; immunosuppression (e.g., prednisolone, rituximab) is for symptomatic patients.

Conclusions:

  • FV-INH is a rare but potentially severe condition requiring careful diagnosis and management.
  • Treatment decisions should be individualized based on bleeding risk and patient symptoms.
  • Further research is needed to establish definitive treatment guidelines.